Heron Therapeutics, Inc. (HRTX) Stock Grade

About Heron Therapeutics, Inc.'s fundamentals

Heron Therapeutics is a small-cap biotechnology company with a market capitalization of $55.2 million that generated 7.4% year-over-year revenue growth in its latest reporting period. However, the company operates at a net loss, with a negative net margin of -13.0%, meaning it spent more on operating expenses than it generated in revenue. The company does not currently pay a dividend, which is typical for early-stage biotech firms focused on research and development spending. Profitability metrics like P/E ratio and return on equity are not meaningful given the company's loss-making status.